Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

Tempus AI, Inc.'s unique data assets and AI-driven oncology solutions make it a promising buy. Click to read more on why the ...

In the assessment of 12-month price targets, analysts unveil insights for Tempus AI, presenting an average target of $64.09, ...

Tempus AI TEM and Butterfly Network BFLY are two AI-driven healthcare infotech companies that have successfully reformed diagnostics through their complementary approaches. Tempus AI is leading the ...

The deals call for Pathos AI, another Chicago company co-founded by Lefkofsky, to build the oncology model using Tempus data, for which it will pay Tempus $200 million in data licensing and model ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Tempus’ business is structured across three pillars, each with distinct growth and margin profiles. Tempus AI carries an average analyst price target of $61.40, with a tight range between $48 ...

Tempus AI’s business is divided into several key segments, with genomics representing the largest revenue contributor. Genomics revenue reached $193.8 million in Q1 2025, an 88.9% increase year ...

Tempus AI shares are trading lower by 1.3% Tuesday afternoon. The company will report its Q1 earnings after Tuesday’s market close. Memorial Day Special: Access your full investing command ...